Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Clinical and epidemiologic studies suggest that a number of factors are associated with the risk of migraine and precipitation of an attack. However, the degree to which causal associations can be inferred from reported studies is very limited and is a result of the methodological problems discussed throughout this review. The study of migraine in many ways parallels the pattern seen in early investigations of other conditions, such as rheumatoid arthritis and systemic lupus erythematosus, because a number of methodological problems had to be resolved in the study of these conditions before significant progress could be made. To achieve significant advances in the improvement of our understanding of the causes of migraine, a number of related issues must be addressed and resolved in future studies. Most noteworthy among these are Recognition of the probable heterogeneity of migraine, not merely in the manifestation of symptoms but, more importantly, in the existence of distinct etiologic subtypes. A number of findings suggest that some migraine subtypes are sensitive to certain precipitants, some appear to be a part of a more generalized constitutional disorder, and some are accompanied by a higher prevalence of migraine among family members. Efforts should be made in understanding the relationship between specific biochemical markers and traits (such as monoamine oxidase deficiency and tyramine sensitivity); precipitants related to the migraine attack; and epidemiologic characteristics such as age at onset and sex. Creation of a more precise, reliable, and practically useful definition of migraine. Without such a definition, it is difficult, if not impossible, to compare results between studies, to understand the relationship between risk factors and migraine subtypes, to understand properly associations identified in selected clinic populations, and, in general, to understand the epidemiology of migraine. More accurate characterization of the case group under study. More documentation of the age at onset, symptoms, frequency of attacks, and other characteristics related to migraine would be very useful to compare properly results between studies. Additional descriptive epidemiologic studies of migraine which would include reliable estimates of age-specific incidence, prevalence, remission rates, and natural history of the various migraine subtypes.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Migraine headache: epidemiologic perspectives. 609 21

The serum concentration of several markers in patients with collagen disease was studied to evaluate the useful indices for the diagnosis of interstitial pneumonia/pulmonary fibroses (pneumonitis). Procollagen N-terminal type III peptides, type IV collagen and monoamine oxidase were measured as the fibrosing markers. Squamous cell related antigen (SCC) and soluble cytokeratin 19 fragments (CYFRA21-1) were measured as the tumor markers. Hyaluronic acid, ESR and CRP were measured as the inflammation markers. The 119 patients with collagen disease (71 patients with RA, 16 with SSc, 9 with SLE, 8 with PM/DM, 6 with MCTI) and 9 with other collagen diseases) who have been followed in our hospital were studied. Of 119 patients, 23 patients (RA14, SSc7, PM/DM2) were complicated with pneumonitis. The results were as follows. 1. All the serum markers except CYFRA21-1 had no significantly difference between with and without pneumonitis. The serum CYFRA21-1 level in the pneumonitis group was higher than that of the non pneumonitis group (1.38 vs 0.66 ng/ml, P < 0.001). 2. The cut-off value was set at 2.0 ng/ml, corresponding to 26.1% sensitivity and 97.9% specificity for pneumonitis complicated with collagen disease. 3. The CYFRA21-1 level in early stage of pneumonitis group (from onset to measurement < 1 year) was significantly higher than that of late stage group (from onset to measurement > 1 year). And there are 75.0% sensitivity in early stage of pneumonitis group. 4. Case study was suggested that CYFRA21-1 had a potential as a diagnostic and monitoring marker for pneumonitis.
 ...
PMID:[Studies of serum markers in patients with interstitial pneumonia/pulmonary fibrosis complicated with collagen diseases: clinical evaluation of CYFRA21-1]. 912 23